|
|
Post by agedhippie on Apr 10, 2023 22:39:33 GMT -5
Understood but paying anything, especially double digit royalties in perpetuity, is not total control. It's fine to have a different opinion. They are paying royalties on the net sales rather than gross revenue. Once you have pulled all the sales costs out that headline double digit royalty is greatly reduced, and that's what they will be looking at. It's not impossible that they would buy MNKD, but I think it is unlikely because the RoI would be hard to justify - it would be years before they recovered that purchase. |
|
|
|
Post by akemp3000 on Apr 11, 2023 6:27:00 GMT -5
I don't agree. IMO, the royalties, even on net sales, are on a path to grow and accelerate versus being "greatly reduced". Add to this, the next UTHR undisclosed molecule that if successful, might easily justify the ROI. Granted, this is why there's no way of knowing when UTHR might decide to make a move for total control.
|
|
|
|
Post by hellodolly on Apr 11, 2023 6:27:55 GMT -5
Understood but paying anything, especially double digit royalties in perpetuity, is not total control. It's fine to have a different opinion. They are paying royalties on the net sales rather than gross revenue. Once you have pulled all the sales costs out that headline double digit royalty is greatly reduced, and that's what they will be looking at. It's not impossible that they would buy MNKD, but I think it is unlikely because the RoI would be hard to justify - it would be years before they recovered that purchase. When does it pay? After paying royalties on net sales for two indications, three indications or more? Personally, I'll take royalties into perpetuity, myself. Especially on drugs, when combined overall as part of the business platform like MNKD TS, can help bring in billions in top line revenue each year for the partner(s) and we always get to take a slice as we sit at the table. The pie just keeps coming around 4X a year. To me, that's as good as or even better than the 'subscription model' used in various other business applications. |
|
|
|
Post by sayhey24 on Apr 11, 2023 6:38:19 GMT -5
Understood but paying anything, especially double digit royalties in perpetuity, is not total control. It's fine to have a different opinion. They are paying royalties on the net sales rather than gross revenue. Once you have pulled all the sales costs out that headline double digit royalty is greatly reduced, and that's what they will be looking at. It's not impossible that they would buy MNKD, but I think it is unlikely because the RoI would be hard to justify - it would be years before they recovered that purchase. And, cost+ on manufacturing which adds back in. All I know is sitting sub four on pss has got to stop and the board needs to do something. Maybe they could have started by having an in-person ASM. Post Covid there is a lot of interest in inhalable drugs and technosphere would seem to be in the sweet spot. I think we need someone who can shake some trees and get some deals going. |
|
|
|
Post by mango on Apr 11, 2023 6:55:09 GMT -5
We have several drugs in the pipeline being developed that we will make significantly more from going solo than we ever will making a few more partnership deals.
|
|
|
|
Post by awesomo on Apr 11, 2023 7:18:27 GMT -5
We have several drugs in the pipeline being developed that we will make significantly more from going solo than we ever will making a few more partnership deals. I’m not sure how you can say this about a company that bungled their supposed blockbuster drug and has yet to effectively sell and market any drug/product. The UTHR partnership is the main reason the company is in still alive and in position to do things. |
|
|
|
Post by akemp3000 on Apr 11, 2023 8:52:13 GMT -5
We have several drugs in the pipeline being developed that we will make significantly more from going solo than we ever will making a few more partnership deals. I’m not sure how you can say this about a company that bungled their supposed blockbuster drug and has yet to effectively sell and market any drug/product. The UTHR partnership is the main reason the company is in still alive and in position to do things. Both seem to be fair perspectives. In hindsight, some believe Al Mann should have never pursued diabetes as the first Technosphere challenge as it was and remains the highest and most difficult mountain to climb. It would probably have been better for Al to pursue a couple of smaller indications first. That said, I believe Mango's spot on and the company's bright future shouldn't be judged based on difficulties of the past. |
|
|
|
Post by prcgorman2 on Apr 11, 2023 8:54:02 GMT -5
We have several drugs in the pipeline being developed that we will make significantly more from going solo than we ever will making a few more partnership deals. I’m not sure how you can say this about a company that bungled their supposed blockbuster drug and has yet to effectively sell and market any drug/product. The UTHR partnership is the main reason the company is in still alive and in position to do things. Afrezza is the main reason the company is still alive, and Tyvaso DPI is the reason the company is set to thrive. There were years (and a global pandemic) in between those two milestones that should not be ignored, and prior to having Afrezza dumped back in their lap, the plan was NEVER to self-market Afrezza. I have to say, if I was as disgusted as you and caesar, I simply would not be invested in MannKind, period. I notice when our SP is buoyant and increasing you're not satisfied, and when it's hit back (but not to where it was prior to Tyvaso DPI), you're downright dismissive. Bless you for having the patience to stay with a company you apparently hate. |
|
|
|
Post by awesomo on Apr 11, 2023 9:06:13 GMT -5
I’m not sure how you can say this about a company that bungled their supposed blockbuster drug and has yet to effectively sell and market any drug/product. The UTHR partnership is the main reason the company is in still alive and in position to do things. Afrezza is the main reason the company is still alive, and Tyvaso DPI is the reason the company is set to thrive. There were years (and a global pandemic) in between those two milestones that should not be ignored, and prior to having Afrezza dumped back in their lap, the plan was NEVER to self-market Afrezza. I have to say, if I was as disgusted as you and caesar, I simply would not be invested in MannKind, period. I notice when our SP is buoyant and increasing you're not satisfied, and when it's hit back (but not to where it was prior to Tyvaso DPI), you're downright dismissive. Bless you for having the patience to stay with a company you apparently hate. UTHR partnership started in 2018, long before the pandemic started. Afrezza has been hemorrhaging money since it received approval and it's still losing money to this day. The thing that kept MannKind alive before was financing and fundraising on the back of investors. UTHR is the reason why we aren't in a death spiral. |
|
|
|
Post by thekid2499 on Apr 11, 2023 9:30:44 GMT -5
Afrezza is the main reason the company is still alive, and Tyvaso DPI is the reason the company is set to thrive. There were years (and a global pandemic) in between those two milestones that should not be ignored, and prior to having Afrezza dumped back in their lap, the plan was NEVER to self-market Afrezza. I have to say, if I was as disgusted as you and caesar, I simply would not be invested in MannKind, period. I notice when our SP is buoyant and increasing you're not satisfied, and when it's hit back (but not to where it was prior to Tyvaso DPI), you're downright dismissive. Bless you for having the patience to stay with a company you apparently hate. UTHR partnership started in 2018, long before the pandemic started. Afrezza has been hemorrhaging money since it received approval and it's still losing money to this day. The thing that kept MannKind alive before was financing and fundraising on the back of investors. UTHR is the reason why we aren't in a death spiral. But you expect the stock price to go up in the future, right? That's why you are invested I assume. Why do you expect the stock price to go up given your negativity on the company and its management? |
|
|
|
Post by awesomo on Apr 11, 2023 9:38:29 GMT -5
UTHR partnership started in 2018, long before the pandemic started. Afrezza has been hemorrhaging money since it received approval and it's still losing money to this day. The thing that kept MannKind alive before was financing and fundraising on the back of investors. UTHR is the reason why we aren't in a death spiral. But you expect the stock price to go up in the future, right? That's why you are invested I assume. Why do you expect the stock price to go up given your negativity on the company and its management? 1. The technology 2. The UTHR partnership leading to other fruitful partnerships I’m not confident in the leadership to do things themselves, they’ve yet to prove it. |
|
|
|
Post by prcgorman2 on Apr 11, 2023 11:36:19 GMT -5
But you expect the stock price to go up in the future, right? That's why you are invested I assume. Why do you expect the stock price to go up given your negativity on the company and its management? 1. The technology 2. The UTHR partnership leading to other fruitful partnerships I’m not confident in the leadership to do things themselves, they’ve yet to prove it. Right, other than they speculatively invested in developing treprostinil which led to the deal with UTHR for developing Tyvaso DPI which they successfully executed on and which was subsequently approved by the FDA, none of which was guaranteed back in 2018, five years ago. See what I mean? You're very very patient even though virtually nobody can tell from what you post.
Also, the financing has done nothing but improve since the current management took over (after the Reverse Split by the previous management). I won't way it's been flawless execution, but I personally find it difficult to complain given what happened in 2015 and where we are now which is we're still here with a presumably bright future. I can't say "epic", but I can say almost miraculous. And did I mention that the CEO said in the last earnings report that Afrezza is already cash flow break even? And I don't know if you've been watching the weekly script information but we're running about 30% growth Year over Year so far in 2023. Pretty remarkable really. But, if none of this is persuasive to you, and you really truly think you own stock in a company managed by idiots, well, I don't think you should blame the management, you should blame yourself.
|
|
|
|
Post by awesomo on Apr 11, 2023 11:50:44 GMT -5
|
|
|
|
Post by letitride on Apr 11, 2023 12:30:10 GMT -5
If it quacks like a duck and it acts like a duck its a duck dress it how ever you like.
|
|
|
|
Post by cretin11 on Apr 11, 2023 12:38:12 GMT -5
All these posts urging awesomo to sell were so persuasive, I was about to pull the trigger but gorman you talked me off the ledge. Not epic (so we can’t accuse you of exaggerating) but “almost miraculous” that we are here, plus “pretty remarkable” Afrezza script growth at 800 TRx in year nine. I guess if we can keep saying “30% year over year” that is comforting. All this and we can still buy shares under $0.80 RS adjusted. Heck no I’m not selling!
|
|
